Mesoblast Limited (MESO) Lifted to “Buy” at Zacks Investment Research
Zacks Investment Research upgraded shares of Mesoblast Limited (NASDAQ:MESO) from a hold rating to a buy rating in a research report sent to investors on Wednesday. The firm currently has $6.50 price target on the stock.
According to Zacks, “Mesoblast Limited is a global leader in developing innovative cell-based medicines. The Company has leveraged its proprietary technology platform, which is based on specialized cells known as mesenchymal lineage adult stem cells, to establish a broad portfolio of late-stage product candidates. Mesoblast’s allogeneic, ‘off-the-shelf’ cell product candidates target advanced stages of diseases with high, unmet medical needs including cardiovascular conditions, orthopedic disorders, immunologic and inflammatory disorders and oncologic/hematologic conditions. “
Other equities analysts also recently issued research reports about the stock. CIBC began coverage on shares of Mesoblast Limited in a research note on Thursday, August 31st. They issued an outperform rating and a $16.00 price target for the company. Maxim Group set a $14.00 price target on shares of Mesoblast Limited and gave the stock a buy rating in a research note on Wednesday, August 16th. Cantor Fitzgerald restated a buy rating and issued a $20.00 price target on shares of Mesoblast Limited in a research note on Wednesday, August 30th. Oppenheimer Holdings, Inc. began coverage on shares of Mesoblast Limited in a research note on Thursday, August 31st. They issued an outperform rating and a $16.00 price target for the company. Finally, ValuEngine downgraded shares of Mesoblast Limited from a hold rating to a sell rating in a research note on Friday, September 15th. Two equities research analysts have rated the stock with a sell rating, two have issued a hold rating and five have given a buy rating to the company. Mesoblast Limited presently has an average rating of Hold and an average target price of $13.14.
Shares of Mesoblast Limited (MESO) opened at 6.15 on Wednesday. The firm’s 50-day moving average price is $5.98 and its 200-day moving average price is $8.03. The stock’s market cap is $522.41 million. Mesoblast Limited has a 12-month low of $4.01 and a 12-month high of $12.50.
ILLEGAL ACTIVITY NOTICE: This piece was first posted by Watch List News and is the property of of Watch List News. If you are accessing this piece on another website, it was illegally stolen and republished in violation of international trademark & copyright laws. The legal version of this piece can be viewed at https://www.watchlistnews.com/mesoblast-limited-meso-lifted-to-buy-at-zacks-investment-research/1615271.html.
Mesoblast Limited Company Profile
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Mesoblast Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mesoblast Limited and related companies with Analyst Ratings Network's FREE daily email newsletter.